ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax of $2.20 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-04-26.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax · last filed 2013-04-26
- ELI LILLY AND COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2013-03-31 was $2.20M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 3 month |
|---|---|
| 2013-03-31 | $2.20M 10-Q · filed 2013-04-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |